Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
WALTHAM, Mass., Feb. 28, 2017 -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced that President and Chief Executive Officer, Robert E. Ward, will present at the Cowen and Company 37th Annual Health Care Conference on Monday, March 6, 2017 at 4:00 p.m. EST at the Boston Marriott Copley Place.
A live audio webcast witll be available on the “Events & Presentations” section of the Company's investor website at www.radiuspharm.com, where a replay will also be available following the presentation.
About Radius
Radius is a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe and a New Drug Application (NDA) has been accepted for filing by the FDA with a PDUFA date of March 30, 2017. The Radius clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug RAD1901 for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Radius' preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for potential use in cancer. For more information, please visit www.radiuspharm.com.
Investor Relations Contact: Barbara Ryan Email: [email protected] Phone: 203-274-2825 Media Contact: Lori Gorski Email: [email protected] Phone: 617-551-4096
